Abstract

Abstract requirements:

• • Character count: You may use up to 3,400 characters. Spaces are included in the character count (tables and graphs do not count as characters if inserted as an image). Abstract authors/co-authors’ names, affiliations, and keywords do not count towards the 3,400-character allowance.
  • Abstracts follow a structured format of introduction, methods, results, and conclusion sections. Tables, graphs, and pictures may be included (tables and graphs do not count as characters if inserted as an image).
  • Images must be in JPEG or PNG format (uploaded images cannot exceed 640w x 480h pixels and 1.5 Megabytes).
  • Case reports that present novel hypotheses, pathologies, treatments, or ethical issues are welcome. However, they are only likely to be selected if the originality is highlighted effectively.
  • Encore abstracts are permissible if both the initial and subsequent conferences allow it. Authors must declare this at the end of the abstract as follows: ‘This abstract was also submitted for the (insert meeting title) congress.’ By submitting, the authors confirm that the organizers of the previous meeting will allow re-submission.
    
  • Declaration of generative AI in scientific writing: authors must disclose the use of generative AI and AI-assisted technologies in the writing process by adding a statement at the end of their abstract, in a new section entitled ‘Declaration of Generative AI and AI-assisted technologies in the writing process’. See below accordion for all information.
  • The maximum number of abstract co-authors that can be listed in an abstract is 15.
  • Please check carefully for typographical errors, misspelled words, misused hyphens, etc. Please also check that your abstract title is correct.
  • Abstracts must be submitted in English.

Submission conditions:

• Accepted abstracts will be published online in Kidney International Reports^®. No printed abstract book will be produced.
• Presenting authors must register for the congress by November 6, 2024, to have their abstract published as described above and to have a poster presentation at the congress. Abstract presenters must register using the same email, if they fail to do so and do not communicate the change of email to the Abstract team, the abstract might not be published in Kidney International Reports® or presented onsite. WCN organizers will not be held responsible for non-publication. 
• If the presenting author cannot present the abstract, a co-author may do so, provided they are registered for the congress. In this case, the original presenting author must communicate the presenting author change to the Abstract team (abstractswcn@theisn.org) to confirm that the new presenting author is registered. Failure to do so will result in the withdrawal of the abstract.
• A non-refundable handling fee of 40 USD is charged per submitted abstract. When submitting the abstract, the handling fee must be paid by credit card (American Express, MasterCard, or Visa). Payment by bank transfer is not possible. Abstract handling fees are waived only for submitters from low-income countries as defined by World Bank income groups listed here. The handling fee for late-breaking clinical trial abstracts is 100 USD and is not waived for submitters from low-income countries.
• Once submitted, abstracts cannot be changed or withdrawn.
• All copyrights are assigned to the ISN.
• All submitted abstracts will be considered for a poster presentation.
• ISN Young Nephrologists Awards: The ISN offers presenting authors under 40 the opportunity to apply for two Young Nephrologists Awards. These awards will cover travel and accommodation costs for attending the congress. Each winner will have an 8-minute oral abstract presentation during a session at the congress. Applications for the awards are only possible during the online abstract submission process.
• Organ trafficking and tourism ethics compliance: Scientific studies and clinical activities must be performed in keeping with the ethical principles outlined in the Declaration of Istanbul on Organ Trafficking and Transplant Tourism. By submitting an abstract, you state that you have not violated any aspect of the Declaration or associated consensus statements on live donation and research on human subjects.

Post-submission:

After submitting your abstract, you will receive a confirmation email within two business days. If the email does not appear, please check your spam folder.

If you submit your abstract on the last day of submission (September 4, 2024) and you do not receive confirmation within 48 hours, please email abstractswcn@theisn.org to make sure your abstract has been received.

Authors of accepted abstracts will be notified by email on October 15, 2024

Late-breaking abstracts cover ground-breaking data that would not otherwise have been presented at WCN’25. If such data are available after the regular abstract deadline, the Scientific Program Working Group will still consider it for presentation.

Late-breaking abstracts describe the latest advances, trial data, and results that have not been previously published or presented and highlight novel and practice-changing studies.

The call for late-breaking abstracts is not an extension of the general submission deadline.

Late-breaking abstract submitters are required to submit a ‘place holder’ abstract during the regular submission period (deadline September 4, 2024). For further information on updating your abstract, please see “Post-Submission” section below.

Preparing a Late-breaking Abstract Submission:

Abstract Requirements:

• Late-breaking abstracts should follow the standard abstract structure: introduction, methods, results and conclusions.
• Late-breaking abstracts should highlight novel and practice-changing studies.

Submission Conditions:

• Late-breaking abstracts will only be considered if a placeholder abstract is submitted during the regular abstract submission period (deadline September 4, 2024). To submit an abstract, please log in to your congress profile and go to “Late-breaking Clinical Trial Abstract(s).”
• A non-refundable handling fee of 100 USD will be charged per abstract submitted in this category. This fee is not waived for applications from low-income countries.
• Late-breaking abstracts will be considered for potential oral presentation in one of the sessions at WCN’25.
• The call for late-breaking abstracts is not an extension of the submission deadline.

Post Submission:

• Updating an abstract Please send a letter of intent to abstractswcn@theisn.org no later than November 6, 2024.
• The abstract submission portal will temporarily re-open until November 6, 2024 for authors to make updates.

The below guidance only refers to the writing process, and not to the use of AI tools to analyze and draw insights from data as part of the research process.

Where authors use generative artificial intelligence (AI) and AI-assisted technologies in the writing process, authors should only use these technologies to improve readability and language. Applying the technology should be done with human oversight and control, and authors should carefully review and edit the result, as AI can generate authoritative-sounding output that can be incorrect, incomplete or biased. AI and AI-assisted technologies should not be listed as an author or co-author, or be cited as an author. Authorship implies responsibilities and tasks that can only be attributed to and performed by humans, as outlined in Kidney International Reports^® publisher’s (Elsevier) AI policy for authors.

Authors should disclose in their abstract the use of AI and AI-assisted technologies in the writing process by following the instructions below. A statement will appear in the published work. Please note that authors are ultimately responsible and accountable for the contents of the work.

Disclosure instructions Authors must disclose the use of generative AI and AI-assisted technologies in the writing process by adding a statement at the end of their abstract, in a new section entitled ‘Declaration of Generative AI and AI-assisted technologies in the writing process’.

Statement: During the preparation of this work the author(s) used [NAME TOOL / SERVICE] in order to [REASON]. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.

This declaration does not apply to the use of basic tools for checking grammar, spelling, references etc. If there is nothing to disclose, there is no need to add a statement.

For abstracts accepted for presentation and publication during WCN’25, the following embargo policy applies.

Embargo Policy